PD-1 expression conditions T cell avidity within an antigen-specific repertoire

The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells

(2015) Gustavo J. Martinez et al.   IMMUNITY

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells

(2015) Pamela M. Odorizzi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

(2015) Andreas D. Ørskov et al.   Oncotarget

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

NFATc1 Regulates PD-1 Expression upon T Cell Activation

(2014) K. J. Oestreich et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma

(2013) N. Labarriere et al.   Clinical & Developmental Immunology

Manipulating the PD-1 pathway to improve immunity

(2013) Alice O Kamphorst et al.   CURRENT OPINION IN IMMUNOLOGY

Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells

(2013) B. Youngblood et al.   JOURNAL OF IMMUNOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

(2011) Ben Youngblood et al.   IMMUNITY

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

(2010) Takashi Inozume et al.   JOURNAL OF IMMUNOTHERAPY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection

(2009) Markus Moll et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes

(2008) Régis Bouquié et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

(2008) Yann Godet et al.   JOURNAL OF EXPERIMENTAL MEDICINE